The BCR-ABL tyrosine kinase inhibitors (TKIs) have shown a remarkable clinical activity in patients with CML, but their efficacy in treating Ph+ B-ALL is limited. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.